Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Leases: 2019-2024

Historic Operating Leases for Crinetics Pharmaceuticals (CRNX) over the last 6 years, with Dec 2024 value amounting to $44.6 million.

  • Crinetics Pharmaceuticals' Operating Leases rose 8.90% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.1 million, marking a year-over-year increase of 8.90%. This contributed to the annual value of $44.6 million for FY2024, which is 6.28% down from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Operating Leases is $44.6 million, which was down 6.28% from $47.6 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Operating Leases high stood at $47.6 million for FY2023, and its period low was $2.0 million during FY2022.
  • Moreover, its 3-year median value for Operating Leases was $44.6 million (2024), whereas its average is $31.4 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Operating Leases slumped by 34.16% in 2022 and then surged by 2,249.56% in 2023.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Operating Leases stood at $4.0 million in 2020, then decreased by 23.42% to $3.1 million in 2021, then tumbled by 34.16% to $2.0 million in 2022, then soared by 2,249.56% to $47.6 million in 2023, then dropped by 6.28% to $44.6 million in 2024.